Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic Merkel cell carcinoma
| Autor: | Chase W. Kwon, Benjamin K. Stoff, Rajini K. Murthy, Ragini R. Kudchadkar |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty programmed death 1 inhibitor Immune checkpoint inhibitors medicine.medical_treatment BP bullous pemphigoid Cancer therapy Case Report Dermatology Pembrolizumab LPP lichen planus pemphigoides immune checkpoint inhibitors Merkel cell carcinoma NSCLC non–small cell lung cancer Internal medicine lcsh:Dermatology medicine skin and connective tissue diseases Adverse effect integumentary system business.industry Immunotherapy lcsh:RL1-803 medicine.disease PD-1 programmed death 1 Lichen planus pemphigoides lichen planus pemphigoides immunotherapy pembrolizumab Bullous pemphigoid business |
| Zdroj: | JAAD Case Reports, Vol 6, Iss 10, Pp 1045-1047 (2020) JAAD Case Reports |
| ISSN: | 2352-5126 |
| DOI: | 10.1016/j.jdcr.2020.03.007 |
| Popis: | Immune checkpoint inhibitors, including pembrolizumab, are novel immunotherapeutic agents that have revolutionized cancer therapy. With increasing use of immunotherapy, early recognition and prompt treatment of associated adverse events are critical to ensure patient safety. Cutaneous toxicities are among the most commonly observed adverse events with this class of drugs. Here we report a novel case of lichen planus pemphigoides (LPP) arising in a patient with metastatic Merkel cell carcinoma treated with pembrolizumab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|